Email this article Analysis of the prevalence of CCR5 coreceptor antagonist resistance mutations among HIV-1 variants in Russia
- Issue: Vol 56, No 3 (2011)
- Pages: 32-37
- Section: Articles
- URL: https://virusjour.crie.ru/jour/article/view/12083
- ID: 12083
Cite item
Full Text
Abstract
The authors studied the prevalence of mutations associated with resistance to the CCR5 coreceptor antagonists maraviroc and vicriviroc in Russia. Most (93.6%) patients infected with HIV-1 genetic subtype A (IDU-A), predominant in the CIS countries, were found to have maraviroc resistance mutations. These mutations appear to reflect the natural genome polymorphism characteristic of the variant IDU-A. Maraviroc resistance mutations were of limited occurrence (2.8%) among the samples of virus subtype B in Russia. There were no vicriviroc resistance mutations in both the HIV-1 genetic variant IDU-A and the samples of virus subtype B. There is a need for further clinical studies evaluating the real impact of these mutations on the efficacy of maraviroc in patients infected with the HIV-1 genetic variant IDU-A.
References
- Beerenwinkel N., Sing T., Lengauer T. et al. Computational methods for the design of effective therapies against drug-resistant HIV strains // Bioinformatics. - 2005. - Vol. 21. - P. 3943-3950.
- Bobkov A., Garaev M. M., Rzhaninova A. et al. Molecular epidemiology of HTV-1 in the former Soviet Union: analysis of env V3 sequences and their correlation with epidemiologic data // AIDS. - 1994. - Vol. 8. - P. 619-624.
- Bobkov A., Kazennova E., Selimova L. et al. A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: Identification of subtype A, subtype B, and novel gagA/ envB recombinants // AIDS Res. Hum. Retrovirus. - 1998. - Vol. 14, N 8. - P. 669-676.
- Jensen M. A., Coetzer M., van't Wout A. B. et al. A Reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences // J. Virol. - 2006. - Vol. 80. - P. 4698-4704.
- Lewis M., Simpson P., Whitcomb J. et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials // 15-th Conference on retroviruses and opportunistic infections. - Boston, 2008. - Poster 871.
- Mori J., Lewis M., Simpson P. et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2 // XVI International HIV Drug Resistance Workshop. - Barbados, 2007. - Abstract 10.
- Soulie C., Maleta I., Lambert-Niclota S. et al. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients // AIDS. - 2008. - Vol. 22. - P. 2212-2214.
- Tsibris A. M., Sagar M., Gulick R. M. et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject // J. Virol. - 2008. - Vol. 82. - P. 8210-8214.
- Westby M., Lewis M., Whitcomb J. et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir // J. Virol. - 2006. - Vol. 80. - P. 4909-4920.
- Westby M., Smith-Burchnell C., Mori J. et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc Utilize Inhibitor-Bound Receptor for Entry // J. Virol. - 2007. - Vol. 81. - P. 2359-2371.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).